Moderna submitted regulatory applications for its mRNA influenza vaccine, mRNA‑1010, to agencies in the U.S., Europe, Canada and Australia, seeking approval for use in adults aged 50 and older. The filing follows pivotal data showing a roughly 27% relative reduction in influenza illness compared with marketed standard‑strain vaccines in the target population. CEO Stéphane Bancel framed the vaccine as a strategic growth product to help Moderna diversify revenue beyond COVID‑19 and RSV programs, and as a platform advantage for faster strain matching. Moderna said approvals would enable geographic expansion of its respiratory vaccine franchise and support future combination vaccine strategies. Regulators will weigh efficacy and safety data against established seasonal-vaccine benchmarks as Moderna pursues broader commercial rollout.